Successful Sale of Evie Rings
Movano Health reported ongoing successful sales and fulfillment of Evie Rings following a back in-stock announcement on September 17.
Anticipated FDA Clearance for EvieMed Ring
Movano Health is in the final stages of the FDA 510(k) review process for the EvieMed ring, with positive progress towards clearance.
B2B Commercial Opportunities
The company is preparing to deliver its first B2B commercial opportunities with healthcare partners shortly after gaining FDA clearance.
Positive Customer Feedback
The company received a consistent 90%-plus customer service approval score, indicating a positive response to improvements in app features, operations, and customer service.
Efficient Customer Acquisition
Movano Health achieved an extremely efficient customer acquisition cost through organic marketing efforts.
Improved Financial Position
The company reported an operating loss of $7.4 million in Q3 2024, an improvement from $9.1 million in the previous year, with a cash reserve of $11.3 million.